How many drugs treat Metastatic renal cell carcinoma?

Drug Landscape tracks 9 marketed treatments for Metastatic renal cell carcinoma (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/metastatic-renal-cell-carcinoma.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Metastatic renal cell carcinoma — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Metastatic renal cell carcinoma (disease) competitive landscape: 9 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

9 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Metastatic renal cell carcinoma, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Opdivo	nivolumab	Bristol-Myers Squibb	Programmed Death Receptor-1 Blocking Antibody [EPC]	Programmed cell death protein 1	2014-01-01
Cometriq	Cabometyx	Exelixis	Kinase Inhibitor	Vascular endothelial growth factor receptor 2	2012-01-01
Cometriq	CABOZANTINIB	Exelixis Inc	Kinase Inhibitor	Vascular endothelial growth factor receptor 2	2012-01-01
Bevacizumab	Bevacizumab-Bvzr	Roche	Monoclonal antibody	Vascular Endothelial Growth Factor (VEGF)	2004-01-01
Avastin	bevacizumab	Roche	Vascular Endothelial Growth Factor Inhibitor [EPC]	Vascular endothelial growth factor A	2004-01-01
Proleukin	ALDESLEUKIN	Chiron	Lymphocyte Growth Factor [EPC]	Interleukin-2 receptor	1992-01-01
Proleukin	Proleukin	University of Minnesota		Interleukin-2 receptor
Pembrolizuma	Pembrolizuma	Memorial Sloan Kettering Cancer Center		Programmed cell death protein 1
Avastin	Avastin	Washington University School of Medicine		Vascular endothelial growth factor A

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Roche · 2 drugs in Metastatic renal cell carcinoma
Chiron · 1 drug in Metastatic renal cell carcinoma
Exelixis · 1 drug in Metastatic renal cell carcinoma
Exelixis Inc · 1 drug in Metastatic renal cell carcinoma
Memorial Sloan Kettering Cancer Center · 1 drug in Metastatic renal cell carcinoma
University of Minnesota · 1 drug in Metastatic renal cell carcinoma
Bristol-Myers Squibb · 1 drug in Metastatic renal cell carcinoma
Washington University School of Medicine · 1 drug in Metastatic renal cell carcinoma

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Metastatic renal cell carcinoma:

Cite this brief

Drug Landscape (2026). Metastatic renal cell carcinoma — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/metastatic-renal-cell-carcinoma. Accessed 2026-06-10.

Metastatic renal cell carcinoma full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing